{"id":"liposomal-doxorubicin-paclitaxel-or-topotecan","safety":{"commonSideEffects":[{"rate":"40–80","effect":"Neutropenia"},{"rate":"30–60","effect":"Anemia"},{"rate":"20–50","effect":"Thrombocytopenia"},{"rate":"30–50","effect":"Nausea/vomiting"},{"rate":"20–40","effect":"Mucositis"},{"rate":"20–40","effect":"Peripheral neuropathy (paclitaxel-related)"},{"rate":"5–15","effect":"Cardiotoxicity (doxorubicin-related)"},{"rate":"15–30","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liposomal doxorubicin intercalates into DNA and generates reactive oxygen species, disrupting replication and transcription. Paclitaxel binds β-tubulin and prevents microtubule depolymerization, halting mitosis. Topotecan inhibits topoisomerase I, preventing DNA unwinding and causing strand breaks. The combination leverages synergistic cytotoxic effects across multiple pathways.","oneSentence":"This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:32.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili)"}]},"trialDetails":[{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT06161025","phase":"PHASE2, PHASE3","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-27","conditions":"Solid Cancer","enrollment":860},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT06855069","phase":"PHASE3","title":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":468},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT04908787","phase":"PHASE3","title":"A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-06-11","conditions":"Ovarian Cancer","enrollment":421},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT06994195","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-04","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":384},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT06751485","phase":"PHASE3","title":"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-01-15","conditions":"Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers","enrollment":430},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT01696032","phase":"PHASE2","title":"SGI-110 in Combination With Carboplatin in Ovarian Cancer","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2012-09","conditions":"Ovarian Cancer","enrollment":120},{"nctId":"NCT03949283","phase":"PHASE3","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cordgenics, LLC","startDate":"2019-07-26","conditions":"Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT00657878","phase":"PHASE3","title":"Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2008-11","conditions":"Ovarian Cancer","enrollment":215},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT01849874","phase":"PHASE3","title":"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-06-27","conditions":"Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer","enrollment":341},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT02282020","phase":"PHASE3","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-06","conditions":"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity","enrollment":266},{"nctId":"NCT00976911","phase":"PHASE3","title":"AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-29","conditions":"Ovarian Cancer","enrollment":361},{"nctId":"NCT04679064","phase":"PHASE3","title":"Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-12-01","conditions":"Ovarian Cancer","enrollment":427},{"nctId":"NCT02903004","phase":"PHASE3","title":"Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2016-04-11","conditions":"Ovarian Neoplasms","enrollment":242},{"nctId":"NCT03699449","phase":"PHASE2","title":"An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-11-26","conditions":"Platinum-resistant Recurrent Ovarian Cancer","enrollment":104},{"nctId":"NCT02822157","phase":"PHASE2","title":"Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-08","conditions":"Ovarian Epithelial Cancer","enrollment":160},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02631876","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"ImmunoGen, Inc.","startDate":"2016-03-02","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":366},{"nctId":"NCT04055038","phase":"PHASE2, PHASE3","title":"Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-09-01","conditions":"Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma","enrollment":164},{"nctId":"NCT00011986","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-01","conditions":"Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":4312},{"nctId":"NCT03367182","phase":"","title":"Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-09-01","conditions":"Ovarian Cancer","enrollment":50},{"nctId":"NCT01593228","phase":"PHASE3","title":"Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Solid Tumors","enrollment":37},{"nctId":"NCT02107378","phase":"PHASE2","title":"Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma","status":"TERMINATED","sponsor":"SOTIO a.s.","startDate":"2014-01","conditions":"Epithelial Ovarian Carcinoma","enrollment":22},{"nctId":"NCT02866370","phase":"PHASE2","title":"Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2015-04","conditions":"Ovarian Clear Cell Carcinoma, Endometrial Clear Cell Carcinoma","enrollment":120},{"nctId":"NCT01121406","phase":"PHASE2","title":"BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04","conditions":"Ovarian Neoplasms","enrollment":110},{"nctId":"NCT00739830","phase":"PHASE2","title":"Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Endometrial Cancer","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3912,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Liposomal doxorubicin, Paclitaxel or Topotecan","genericName":"Liposomal doxorubicin, Paclitaxel or Topotecan","companyName":"Sichuan Baili Pharmaceutical Co., Ltd.","companyId":"sichuan-baili-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells. Used for Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}